Acasti Pharma, Inc. (ACST) CEO Janelle D' Alvise on Q1 2020 Results - Earnings Call Transcript [Seeking Alpha]
Last acasti pharma, inc. - class a earnings: 2/14 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations: acastipharma.com/investors
Acasti Pharma, Inc. (ACST) CEO Janelle D' Alvise on Q1 2020 Results - Earnings Call Transcript Acasti Pharma, Inc. (NASDAQ: ACST Company Participants David Waldman - Crescendo Communications Janelle D' Alvise - President, CEO, Corporate Secretary & Director Jean-François Boily - VP, Finance Pierre Lemieux - Co-Founder, COO & Chief Scientific Officer Brian Groch - Chief Commercial Officer Conference Call Participants Leland Gershell - Oppenheimer Nathan Weinstein - Aegis Capital Corporation George Zavoico - B. Riley FBR, Inc. Operator Good day, ladies and gentlemen, and thank you all for joining us for this Acasti Pharma First Quarter 2020 Earnings Conference Call. [Operator Instructions]. And now to get us started with opening remarks and introductions, I am pleased to turn the floor to David Waldman, Investor Relations for Acasti Pharma. Welcome, David. [Operator Instructions]. Ladies and gentlemen, I do apologize for the delay and I believe we may have lost connection with our prima
[Read more]
| Impact snapshot | Event time: | ACST | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ACST alerts
ACST alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACST alerts
High impacting Acasti Pharma, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ACST
News
- Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in JapanGlobeNewswire
- Acasti Pharma initiates pharmacokinetic bridging study for lead candidate GTX-104 [Seeking Alpha]Seeking Alpha
- Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company's Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid HemorrhageGlobeNewswire
- More
ACST
SEC Filings
- 9/28/21 - Form 3
- 9/23/21 - Form 3
- 9/22/21 - Form 8-K
- ACST's page on the SEC website
- More